AMS | Ticker Profile - Titan Protect

AMS

American Shared Hospital Services

Healthcare · Medical Care Facilities · ASE

$1.33

Data: 2026-05-14

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$11M

Total market value of the company

Trailing P/E

0.00

Forward P/E

4.03

Based on estimated future earnings — lower means cheaper

Rev Growth

-14.8%

Year-over-year revenue change

Profit Margin

-5.5%

How much profit the company keeps from each dollar of revenue

ROE

-9.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+201% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About American Shared Hospital Services

American Shared Hospital Services provides technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. It operates in two segments: Leasing and Direct Patient Service. The company leases nine Gamma Knife systems and one proton beam radiation therapy (PBRT) system; and provides planning, installation, reimbursement, and marketing support services. It also owns and operates two single-unit Gamma Knife facilities that provides radiosurgery services directly to the patient. The company markets its solutions to cancer treatment centers, health systems, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.

https://www.ashs.com

Country: United States Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

203.1% FAIL

Debt must be below 33% of total assets

Cash Ratio

32.4% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$6.00

What our model estimates this business is worth per share

Margin of Safety

77.8%

Deep discount to fair value — significant undervaluation

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

56.8th

Ranks in the top 43% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

95.0

Quality Score

15.0

Combined

42.3

Trading at $2 against a fair value of $6, a 73% discount. Fails ethical screen (Debt ratio). Ranks better than 68% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.640

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1509

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.574

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-36.8%

Historical annualised return based on price data

Max Drawdown

-64.2%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.32

Very low correlation to market moves

52W High

$3.11

57% below the year high

52W Low

$1.25

6% above the year low

Avg Volume

158,488

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.2%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.23

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.78

Moderate leverage — manageable

Current Ratio

0.76

Below 1 means short-term obligations exceed liquid assets — risk flag

Quick Ratio

0.71

Like current ratio but excludes inventory — stricter test

Gross Margin

38.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-14.0%

Profit from core operations before interest and tax

Free Cash Flow

$-3,995,500

Negative — the business is spending more than it generates

Revenue (TTM)

$28M

Total revenue over the last 12 months

Net Income

$-1,553,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$4.00

Target Low

$4.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-03-26	STACHOWIAK RAYMOND C	Officer, Director and Beneficial Owner	100,000	—
2025-06-26	STACHOWIAK RAYMOND C	Officer, Director and Beneficial Owner	110,000	—
2025-04-30	TAGAWA CRAIG KENJI	President	5,613	—
2024-12-19	FRECH RAYMOND SCOTT	Chief Financial Officer	50,000	—
2024-10-14	DELANOIS GARY	Chief Operating Officer	120,000	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Sale	15K–50K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go